|
Sepsis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The HMGB1 gene rs2249825 and rs1045411 site SNPs were associated with sepsis risk, but the rs1360485 site SNP was not associated with sepsis risk.
|
30423384 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
It is interesting that the patterns of change of HMGB1 and SAA over time were distinctive for SIRS and SEPSIS groups.
|
28680349 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, we suggested that miR-181a-5p may play a role in regulating DC responses to HMGB1 and serve as evidence indicating that novel therapies targeting miRNAs may be useful for treating immune dysfunction in the setting of sepsis.
|
28947753 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High-mobility group box 1 (HMGB1) is a nuclear protein that has been found to be a critical mediator of lethality in endotoxemia and sepsis.
|
19097991 |
2009 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) plays a central role in the pathogenesis of sepsis and multiple organ dysfunction syndromes.
|
26632390 |
2016 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Emodin-6-O-β-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo.
|
23146691 |
2013 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The ubiquitous nuclear protein, high mobility group box 1 (HMGB1), is released by activated macrophages and human umbilical vein endothelial cells (HUVECs) and functions as a late mediator of experimental sepsis.
|
26224030 |
2015 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
HMGB1 is implicated as a late mediator of sepsis and is also involved in inflammatory and autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus.
|
24809802 |
2014 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
M-BSA ameliorated LPS-induced sepsis and dextran sulfate sodium (DSS)-induced colitis models in which HMGB1 has been shown to play progressive roles.
|
28338748 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest that HMGB1 accumulation in the late phase of sepsis plays a specific role in the development of postsepsis immunosuppression and specifically affects neutrophil-dependent antibacterial defense mechanisms.
|
27965385 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High Mobility Group Box-1 (HMGB1) is a non-histone nuclear protein that has been implicated in many pathological processes, from sepsis to ischemia.
|
31835864 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
HMGB-1 is considered as an essential facilitator in diseases such as sepsis, collagen disease, atherosclerosis, cancers, arthritis, acute lung injury, epilepsy, myocardial infarction, and local and systemic inflammation.
|
31215389 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The pooled mean differences in biomarker concentration (nonsurvivors - survivors), measured at onset of sepsis, are listed as follows: (1) Ang-1: - 2.9 ng/ml (95% CI - 4.1 to - 1.7, p < 0.01); (2) Ang-2: 4.9 ng/ml (95% CI 2.6 to 7.1, p < 0.01); (3) HMGB1: 1.2 ng/ml (95% CI 0.0 to 2.4, p = 0.05); (4) sRAGE: 1003 pg/ml (95% CI 628 to 1377, p < 0.01); (5) sTREM-1: 87 pg/ml (95% CI 2 to 171, p = 0.04); (6) suPAR: 5.2 ng/ml (95% CI 4.5 to 6.0, p < 0.01).
|
31705327 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to quantify measures of endothelial function, including markers of activation (endocan, Angiopoietin-2 [Ang-2], and von Willebrand Factor), endogenous anticoagulants (tissue factor pathway inhibitor and protein C), and damage-associated factors (High Mobility Group Box 1 [HMGB-1]) in the plasma of patients with sepsis and DIC, and to determine the relationship of these factors with severity of illness and outcome.
|
31140293 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) is a proinflammatory cytokine associated with death from sepsis and other inflammatory diseases.
|
30780033 |
2019 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These observations demonstrate that specific inhibition of endogenous HMGB1 therapeutically reverses lethality of established sepsis indicating that HMGB1 inhibitors can be administered in a clinically relevant time frame.
|
14695889 |
2004 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The mechanism of immunomodulation by mung bean has not been described until today except for a report which identified HMGB1 suppression as a pathway underlying the protective effect against sepsis.
|
28373035 |
2017 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Both HMGB1 and IL-1β have been found to play critical roles in sepsis and post-burn immune dysfunction.
|
29601597 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The exogenous application of the anti-HMGB1 neutralizing antibody improved efferocytosis, vascular integrity and survival rate in sepsis.
|
30235477 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High-mobility group box protein 1 (HMGB1) is a pivotal late mediator involved in the development of sepsis and multiple organ dysfunction syndrome (MODS) in critically ill patients.
|
22047946 |
2012 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum markers associated with the acute proinflammatory phase of sepsis (TNFα, IL-1β, and IL-6) rapidly increased and then progressively decreased during the 30-day period post-CLP, concomitant with a progressive increase in RAGE ligands (S100B, <i>N</i>ϵ-[carboxymethyl]lysine, HSP70, and HMGB1).
|
29127203 |
2018 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
HMGB1 has been associated with divergent clinical conditions such as sepsis, rheumatoid arthritis and atherosclerosis.
|
26605648 |
2015 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High-mobility group box 1 (HMGB1), as a late mediator of sepsis, enhances hyperpermeability, and it is therefore a therapeutic target.
|
25947626 |
2015 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study provides new insights in understanding the molecular mechanisms of HMGB1 secretion in sepsis.
|
25517228 |
2015 |
|
Sepsis
|
0.600 |
Biomarker
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) is a NF released extracellularly as a late mediator of lethality in sepsis and as an early mediator of inflammation following injury.
|
16751357 |
2006 |